11/09/2021
3:15pm - 4:30pm
Track 3: Albrecht Kossel room (Charité)
Event
Panel VI: Assessing the Value of Psychedelic Therapies to Payers and Society
Moderated by: Tura Patterson , M.A.
Psychedelics have a deep history in clinical applications and have recently demonstrated clinical value in a variety of mental illnesses. As the psychedelic clinical value proposition forms, it is also important to understand the economic value proposition. Demonstrating clinical and economic value is the key to assuring sustained access to these promising treatments. This panel will review the current state of mental health treatment and will describe how psychedelics can fill some of the existing gaps in care. The panel will present a conceptual model of the value proposition for psychedelic treatment, and will discuss the challenges and opportunities of conducting economic analyses of emerging psychedelic therapies. Through a conceptual model and case studies of current cost-effectiveness models using MDMA and psilocybin as examples, we will focus on the following issues in determining the value and impact of psychedelic treatments, including:
- -Overview of the epidemiology and costs of mental illnesses
- -Review of limitations of the current standards of care (e.g., treatment ineffectiveness)
- -Review of recent clinical studies of psychedelics
- -Conceptual framework for the psychedelic treatment value proposition
- -Issues in the economic evaluation of psychedelic treatments (including model structure, input data, and quality of life data)
- -Overview of key supply and access issues
Speakers
Elliot Marseille, DrPH, MPP
Charles Raison, M.D.
